| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 30 May 2025 | 22 May 2025 |
| ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve Pursuant to the Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 It is hereby informed you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday 30th May 2025 at 05:30 P.M. at the Registered Office of the Company situated at Darbara Complex SCO-113 District Shopping Centre B Block Ranjit Avenue Amritsar-143001 inter alia transact the following business: 1. To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March 2025. 2. Any other business that may be necessary with the permission of Chairman. Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that at the Board Meeting held today i.e. on Friday, 30th May, 2025, and have Considered and approved the Audited Standalone and Consolidated Financial Results for the Quarter and Financial Year ended 31st March, 2025. The said Audited Financial Results were reviewed by Audit Committee and thereafter approved by the Board of Directors. (As Per BSE Announcement Dated on: 30/05/2025) | ||
| Board Meeting | 12 Mar 2025 | 12 Mar 2025 |
| Pursuant to Regulation 30 of SEBI (LODR), Regulations 2015, the Board of Directors at the meeting held on today March 12, 2025 have considered and appointed Ms. Harshita Aggarwal as the Company Secretary and Compliance Officer of the company w.e.f March 12, 2025. | ||
| Board Meeting | 14 Feb 2025 | 6 Feb 2025 |
| ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve the Unaudited Standalone & Consolidated Financial Results for the Quarter and Nine months ended December 31 2024 along with Limited Review Report. Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 (Listing Regulations), this is to inform your that Board of Directors in its meeting held today i.e., February 14, 2025, have inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024, along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith. (As Per BSE Announcement Dated on: 14/02/2025) | ||
| Board Meeting | 14 Nov 2024 | 7 Nov 2024 |
| ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve 1. To consider and approve the Unaudited Standalone & Consolidated Financial Results along with Limited Review Report thereon for the Quarter and Half year ended 30th September 2024. 2. Transact any other matter if any with permission of chairman. Pursuant to the SEBI [Prohibition of Insider Trading] Regulation and policy on Code of conduct for prevention of Insider Trading and Fair Disclosure of Unpublished Price Sensitive Information of the Company the Trading Window stands closed from 01st October 2024 and will end on 48 hours after the results are made public on 14th November 2024. Pursuant to Regulation 30 of SEBI (LODR), 2015, enclosed are the Unaudited Standalone & Consolidated Financial Results for the quarter and half year ended 30.09.2024. (As Per BSE Announcement Dated on: 14/11/2024) | ||
| Board Meeting | 14 Aug 2024 | 7 Aug 2024 |
| ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve Pursuant to Reg. 29 of SEBI (LODR) 2015 it is hereby informed you that the Baord meeting is scheduled to be held on 14th August 2024. Please enclosed herewith BM notice for your reference. Please find and attached herewith enclosed the Outcome of Board Meeting held on today i.e. 14.08.2024 (As per BSE Announcement dated on 14/08/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.